20 years ago, European pharmaceutical legislation underwent a major review, a critical point in the continent’s single market in healthcare. Since then Europe has grown, bringing new voices, political momentum and advanced technologies into healthcare and today, the European Commission is reshaping pharma legislation to meet the twin priorities of equality of access and ability to pay.
This is a significant moment for the global biopharmaceutical industry and one that will change the dynamics of investment, science and market access for companies worldwide.
How does the legislative framework for medicines achieve its aims through reform? Balancing equity and affordability of medicines with reward for high-risk innovation from SMEs through to multi-nationals.
- The drive for reform – the world is changing and with it must change the pathway for medicines so that all patients benefit
- What do SMEs, mid-sized and multi-national companies need from legislation to ensure they can deliver innovation in the long term?
- When change is inevitable, how does industry roll up its shelves and help collectively drive a new future, rather than waiting for it to be imposed?
- How will European reform impact the global biopharma sector in a time of geopolitical realignment and regrowth?